A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial

Lupus Science and Medicine

Volumn 2, Issue 1, 2015, Pages

  Tamirou, Farah ^a   Lauwerys, Bernard R ^a   Dall'Era, Maria ^b   Mackay, Meggan ^c   Rovin, Brad ^d   Cervera, Ricard ^e   Houssiau, Frédéric A ^a   Abramowicz, Daniel ^f   Atzeni, Fabiola ^g   Blockmans, Daniel ^h   Danieli, Maria Giovanna ⁱ   De Clercq, Luc ^j   D'Cruz, David ^k   Del Mar Ayala Guttierez, Maria ^l   De Ramon Garrido, Enrique ^l   Gilboe, Inge Magrethe ^m   De Keyser, Filip ⁿ   Delahousse, Michel ^o   Espinosa, Gerard ^p   Fiehn, Christoph ^q   Golstein, Marc ^r   Guillevin, Loïc ^s   Hirsch, Marco ^t   Karras, Alexandre ^u   Lang, Philippe ^v   Le Guern, Véronique ^s   Marchal, Martine ^w   Marinho, Antonio ^x   Max, Regina ^y   Peeters, Patrick ⁿ   Petera, Peter ^z   Petrovic, Radmila ^aa   Quémeneur, Thomas ^ab   Raeman, Frank ^ac   Remy, Philippe ^v   Ravelingien, Isabelle ^ad   Sarzi Puttini, Piercarlo ^g   Sangle, Shirish ^k   Tektonidou, Maria ^ae   De Santis, Lucia Valiente ^l   Vasconcelos, Carlos ^x   Verresen, Luc ^af   Weiss, Laurence ^u   Westhovens, René ^h   more..

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f ERASME HOSPITAL   (Belgium)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^j SINT AUGUSTINUS HOSPITAL   (Belgium)

^k ST THOMAS HOSPITAL   (United Kingdom)

^l HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

^o FOCH HOSPITAL   (France)

^p HOSPITAL CLÍNIC   (Spain)

^q ACURA Center for Rheumatic Diseases   (Germany)

^r Service de Rheumatologie   (Belgium)

^s Institut Cochin   (France)

^t Grand Duchy of Luxembourg   (Luxembourg)

^u HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^v HENRI MONDOR HOSPITAL   (France)

^w Cardiology   (Belgium)

^x HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^y UNIVERSITY OF HEIDELBERG   (Germany)

^z GENERAL HOSPITAL LINZ   (Austria)

^aa UNIVERSITY OF BELGRADE   (Serbia)

^ab LILLE UNIVERSITY HOSPITAL   (France)

^ac Jan Palfijn Hospital   (Belgium)

^ad OLV HOSPITAL   (Belgium)

^ae UNIVERSITY OF ATHENS   (Greece)

^af DEPARTMENT OF CARDIOLOGY   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; TREATMENT DURATION; URINALYSIS; VALIDATION STUDY;

EID: 84949191564     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2015-000123     Document Type: Article

References (10)

1. Costenbader KH, Desai A, Alarcón GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011;63:1681-8.
2. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephriti Trial. Arthritis Rheum 2004;50:3934-40.
3. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4.
4. Korbet SM, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: The predictive value of a ?50% reduction in proteinuria at 6 months. Nephrol Dial Transplant 2013;28:2313-18.
5. Tamirou F, D'Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2015.
6. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305-13.
7. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: result from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
8. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32.
9. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
10. Thamer M, Hernán MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36: 560-4.